Biogen Inc.
BIIB Healthcare Drug Manufacturers General
Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024. In the quarter to June 2026, revenue grew 3.42%, EPS fell 84.8%, free cash flow grew 103.3% and total debt rose 16.0%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
Follow BIIB
Biogen Inc. (BIIB) Operating cash flow
Biogen Inc.'s operating cash flow for fiscal 2025 was $2.2B, down 23.3% from $2.9B in fiscal 2024. Over the twelve months to 30 June 2026 it was $2.9B. Over the past ten years it has ranged from $1.4B (fiscal 2022) to $7.1B (fiscal 2019); the current reading is higher than 27% of that period. Biogen Inc. ranks 14th of 21 Drug Manufacturers General companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $2.2B | (23.33%) |
| FY2024 | $2.9B | 85.85% |
| FY2023 | $1.5B | 11.77% |
| FY2022 | $1.4B | (61.97%) |
| FY2021 | $3.6B | (13.95%) |
| FY2020 | $4.2B | (40.25%) |
| FY2019 | $7.1B | 14.40% |
| FY2018 | $6.2B | 35.96% |
| FY2017 | $4.6B | (0.79%) |
| FY2016 | $4.6B | 17.04% |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | $448.9M | (30.46%) |
| Mar 2026 | $645.5M | 26.10% |
| Dec 2025 | $511.9M | (59.77%) |
| Sep 2025 | $1.3B | 690.86% |
| 42 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| SNY Sanofi compare | $21.6B |
| NVO Novo Nordisk A/S compare | $20.4B |
| AZN AstraZeneca PLC compare | $13.7B |
| GILD Gilead Sciences, Inc. compare | $13.6B |
| PFE Pfizer Inc. compare | $13.4B |
| BMY Bristol Myers Squibb Company compare | $12.8B |
| AMGN Amgen Inc. compare | $12.5B |
| GSK GSK PLC Sponsored ADR compare | $11.0B |
| BIIB Biogen Inc. | $2.9B |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on BIIB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement